erlotinib hydrochloride has been researched along with Hepatitis C, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumert, TF; Doffoël, M; Habersetzer, F; Lupberger, J; Saviano, A; Schmidt-Mutter, C; Schuster, C; Simo-Noumbissie, P | 1 |
| Bardou-Jacquet, E; Guyader, D; Lorho, R | 1 |
1 trial(s) available for erlotinib hydrochloride and Hepatitis C, Chronic
| Article | Year |
|---|---|
Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; ErbB Receptors; Erlotinib Hydrochloride; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Prospective Studies; RNA | 2022 |
1 other study(ies) available for erlotinib hydrochloride and Hepatitis C, Chronic
| Article | Year |
|---|---|
Kinase inhibitors in the treatment of chronic hepatitis C virus.
Topics: Adult; Antiviral Agents; Erlotinib Hydrochloride; Fatal Outcome; Follow-Up Studies; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Protein Kinase Inhibitors; Quinazolines | 2011 |